ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Peptide-Radionuclide Conjugates (PRCs) Market Research Report 2026
Published Date: 2026-02-06
|
Report Code: QYRE-Auto-6N20185
Home | Market Reports
Global Peptide Radionuclide Conjugates PRCs Market Outlook In Depth Analysis Forecast to 2031
BUY CHAPTERS

Global Peptide-Radionuclide Conjugates (PRCs) Market Research Report 2026

Code: QYRE-Auto-6N20185
Report
2026-02-06
Pages:114
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Novartis
RadioMedix
Curium Pharma
Telix Pharmaceutical
ITM Radiopharma
Grand Pharmaceutical

Peptide-Radionuclide Conjugates (PRCs) Market

The global Peptide-Radionuclide Conjugates (PRCs) market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Peptide-Radionuclide Conjugates (PRCs) competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Peptide-Radionuclide Conjugates (PRCs) are advanced therapeutic and diagnostic tools used in nuclear medicine that combine a peptide, which specifically binds to certain receptors on cancer cells, with a radionuclide, which emits radiation. The peptide component targets and binds to receptors that are overexpressed on the surface of tumor cells, such as somatostatin receptors in neuroendocrine tumors. The attached radionuclide then emits either beta or alpha particles, which deliver targeted radiation directly to the cancer cells, leading to their destruction. This combination allows for highly specific treatment of cancerous tissues while minimizing damage to surrounding healthy tissues, making PRCs valuable in both imaging (for diagnosis) and therapy (for treatment).
The market for Peptide-Radionuclide Conjugates (PRCs) is experiencing significant growth, driven by advances in targeted cancer therapies and diagnostics. The increasing prevalence of cancers that express specific receptors, such as neuroendocrine tumors, has led to a rising demand for PRCs. These conjugates offer precise targeting and localized radiation treatment, making them a valuable tool in oncology. Additionally, the approval and commercialization of PRCs like ^177Lu-DOTATATE (Lutathera) have spurred interest and investment in this niche market, contributing to its expansion.
Recent trends highlight substantial progress in both the development and application of PRCs. Ongoing research and clinical trials are focused on improving the efficacy, safety, and specificity of these therapies. Innovations include the development of new peptides with enhanced receptor binding properties and novel radionuclides that may offer better therapeutic outcomes or reduced side effects. This research is not only expanding the indications for existing PRCs but also paving the way for new therapeutic and diagnostic options, further driving market growth.
Despite the positive outlook, the PRC market faces several challenges. High costs associated with the development and manufacturing of PRCs, along with the complexity of their production, can limit market accessibility and adoption. Additionally, competition from other targeted therapies and advancements in immunotherapy may influence market dynamics. Nevertheless, the continuous innovation in PRC technologies and the increasing number of clinical indications are likely to sustain market growth, offering promising prospects for both existing and emerging products in the sector.
This report delivers a comprehensive overview of the global Peptide-Radionuclide Conjugates (PRCs) market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Peptide-Radionuclide Conjugates (PRCs). The Peptide-Radionuclide Conjugates (PRCs) market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Peptide-Radionuclide Conjugates (PRCs) market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Peptide-Radionuclide Conjugates (PRCs) manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Peptide-Radionuclide Conjugates (PRCs) Market Report

Report Metric Details
Report Name Peptide-Radionuclide Conjugates (PRCs) Market
Segment by Type
  • Diagnostic PRCs
  • Therapeutic PRCs
by Application
  • Prostate Cancer
  • Neuroendocrine Tumors
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Novartis, RadioMedix, Curium Pharma, Telix Pharmaceutical, ITM Radiopharma, Grand Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Peptide-Radionuclide Conjugates (PRCs) manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Peptide-Radionuclide Conjugates (PRCs) sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Peptide-Radionuclide Conjugates (PRCs) Market report?

Ans: The main players in the Peptide-Radionuclide Conjugates (PRCs) Market are Novartis, RadioMedix, Curium Pharma, Telix Pharmaceutical, ITM Radiopharma, Grand Pharmaceutical

What are the Application segmentation covered in the Peptide-Radionuclide Conjugates (PRCs) Market report?

Ans: The Applications covered in the Peptide-Radionuclide Conjugates (PRCs) Market report are Prostate Cancer, Neuroendocrine Tumors, Other

What are the Type segmentation covered in the Peptide-Radionuclide Conjugates (PRCs) Market report?

Ans: The Types covered in the Peptide-Radionuclide Conjugates (PRCs) Market report are Diagnostic PRCs, Therapeutic PRCs

1 Peptide-Radionuclide Conjugates (PRCs) Market Overview
1.1 Product Definition
1.2 Peptide-Radionuclide Conjugates (PRCs) by Type
1.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Market Value by Type: 2025 vs 2032
1.2.2 Diagnostic PRCs
1.2.3 Therapeutic PRCs
1.3 Peptide-Radionuclide Conjugates (PRCs) by Application
1.3.1 Global Peptide-Radionuclide Conjugates (PRCs) Market Value by Application: 2025 vs 2032
1.3.2 Prostate Cancer
1.3.3 Neuroendocrine Tumors
1.3.4 Other
1.4 Global Peptide-Radionuclide Conjugates (PRCs) Market Size Estimates and Forecasts
1.4.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue 2021–2032
1.4.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales 2021–2032
1.4.3 Global Peptide-Radionuclide Conjugates (PRCs) Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Peptide-Radionuclide Conjugates (PRCs) Market Competition by Manufacturers
2.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Manufacturers (2021–2026)
2.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Peptide-Radionuclide Conjugates (PRCs) Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Peptide-Radionuclide Conjugates (PRCs), Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Peptide-Radionuclide Conjugates (PRCs), Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Peptide-Radionuclide Conjugates (PRCs), Product Types and Applications
2.7 Global Key Manufacturers of Peptide-Radionuclide Conjugates (PRCs), Date of Entry into the Industry
2.8 Global Peptide-Radionuclide Conjugates (PRCs) Market Competitive Situation and Trends
2.8.1 Global Peptide-Radionuclide Conjugates (PRCs) Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Peptide-Radionuclide Conjugates (PRCs) Players Market Share by Revenue
2.8.3 Global Peptide-Radionuclide Conjugates (PRCs) Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Peptide-Radionuclide Conjugates (PRCs) Market Scenario by Region
3.1 Global Peptide-Radionuclide Conjugates (PRCs) Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region: 2021–2032
3.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region: 2021–2026
3.2.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region: 2027–2032
3.3 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Region: 2021–2032
3.3.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Region: 2021–2026
3.3.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Region: 2027–2032
3.4 North America Peptide-Radionuclide Conjugates (PRCs) Market Facts & Figures by Country
3.4.1 North America Peptide-Radionuclide Conjugates (PRCs) Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021–2032)
3.4.3 North America Peptide-Radionuclide Conjugates (PRCs) Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Peptide-Radionuclide Conjugates (PRCs) Market Facts & Figures by Country
3.5.1 Europe Peptide-Radionuclide Conjugates (PRCs) Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021–2032)
3.5.3 Europe Peptide-Radionuclide Conjugates (PRCs) Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Peptide-Radionuclide Conjugates (PRCs) Market Facts & Figures by Region
3.6.1 Asia Pacific Peptide-Radionuclide Conjugates (PRCs) Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Peptide-Radionuclide Conjugates (PRCs) Sales by Region (2021–2032)
3.6.3 Asia Pacific Peptide-Radionuclide Conjugates (PRCs) Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Peptide-Radionuclide Conjugates (PRCs) Market Facts & Figures by Country
3.7.1 Latin America Peptide-Radionuclide Conjugates (PRCs) Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021–2032)
3.7.3 Latin America Peptide-Radionuclide Conjugates (PRCs) Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Peptide-Radionuclide Conjugates (PRCs) Market Facts & Figures by Country
3.8.1 Middle East and Africa Peptide-Radionuclide Conjugates (PRCs) Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021–2032)
3.8.3 Middle East and Africa Peptide-Radionuclide Conjugates (PRCs) Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021–2032)
4.1.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021–2026)
4.1.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2027–2032)
4.1.3 Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type (2021–2032)
4.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2021–2032)
4.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2021–2026)
4.2.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2027–2032)
4.2.3 Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Type (2021–2032)
4.3 Global Peptide-Radionuclide Conjugates (PRCs) Price by Type (2021–2032)
5 Segment by Application
5.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021–2032)
5.1.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021–2026)
5.1.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2027–2032)
5.1.3 Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Application (2021–2032)
5.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2021–2032)
5.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2021–2026)
5.2.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2027–2032)
5.2.3 Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Application (2021–2032)
5.3 Global Peptide-Radionuclide Conjugates (PRCs) Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Company Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Novartis Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 RadioMedix
6.2.1 RadioMedix Company Information
6.2.2 RadioMedix Description and Business Overview
6.2.3 RadioMedix Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 RadioMedix Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
6.2.5 RadioMedix Recent Developments/Updates
6.3 Curium Pharma
6.3.1 Curium Pharma Company Information
6.3.2 Curium Pharma Description and Business Overview
6.3.3 Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
6.3.5 Curium Pharma Recent Developments/Updates
6.4 Telix Pharmaceutical
6.4.1 Telix Pharmaceutical Company Information
6.4.2 Telix Pharmaceutical Description and Business Overview
6.4.3 Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
6.4.5 Telix Pharmaceutical Recent Developments/Updates
6.5 ITM Radiopharma
6.5.1 ITM Radiopharma Company Information
6.5.2 ITM Radiopharma Description and Business Overview
6.5.3 ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
6.5.5 ITM Radiopharma Recent Developments/Updates
6.6 Grand Pharmaceutical
6.6.1 Grand Pharmaceutical Company Information
6.6.2 Grand Pharmaceutical Description and Business Overview
6.6.3 Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
6.6.5 Grand Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Peptide-Radionuclide Conjugates (PRCs) Industry Chain Analysis
7.2 Peptide-Radionuclide Conjugates (PRCs) Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Peptide-Radionuclide Conjugates (PRCs) Production Mode & Process Analysis
7.4 Peptide-Radionuclide Conjugates (PRCs) Sales and Marketing
7.4.1 Peptide-Radionuclide Conjugates (PRCs) Sales Channels
7.4.2 Peptide-Radionuclide Conjugates (PRCs) Distributors
7.5 Peptide-Radionuclide Conjugates (PRCs) Customer Analysis
8 Peptide-Radionuclide Conjugates (PRCs) Market Dynamics
8.1 Peptide-Radionuclide Conjugates (PRCs) Industry Trends
8.2 Peptide-Radionuclide Conjugates (PRCs) Market Drivers
8.3 Peptide-Radionuclide Conjugates (PRCs) Market Challenges
8.4 Peptide-Radionuclide Conjugates (PRCs) Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Novartis
RadioMedix
Curium Pharma
Telix Pharmaceutical
ITM Radiopharma
Grand Pharmaceutical
List of Tables
 Table 1. Global Peptide-Radionuclide Conjugates (PRCs) Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Peptide-Radionuclide Conjugates (PRCs) Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global Peptide-Radionuclide Conjugates (PRCs) Market Competitive Situation by Manufacturers in 2025
 Table 4. Global Peptide-Radionuclide Conjugates (PRCs) Sales (K Units) of Key Manufacturers (2021–2026)
 Table 5. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global Peptide-Radionuclide Conjugates (PRCs) Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market Peptide-Radionuclide Conjugates (PRCs) Average Price (US$/Unit) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of Peptide-Radionuclide Conjugates (PRCs), Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of Peptide-Radionuclide Conjugates (PRCs), Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of Peptide-Radionuclide Conjugates (PRCs), Product Types and Applications
 Table 12. Global Key Manufacturers of Peptide-Radionuclide Conjugates (PRCs), Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Peptide-Radionuclide Conjugates (PRCs) Companies by Tier (Tier 1, Tier 2, Tier 3), based on Peptide-Radionuclide Conjugates (PRCs) Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Peptide-Radionuclide Conjugates (PRCs) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region (K Units), 2021–2026
 Table 18. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Region (2021–2026)
 Table 19. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region (K Units), 2027–2032
 Table 20. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Region (2027–2032)
 Table 21. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Region (US$ Million), 2021–2026
 Table 22. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Region (2021–2026)
 Table 23. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Region (US$ Million), 2027–2032
 Table 24. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Region (2027–2032)
 Table 25. North America Peptide-Radionuclide Conjugates (PRCs) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America Peptide-Radionuclide Conjugates (PRCs) Sales by Country (K Units), 2021–2026
 Table 27. North America Peptide-Radionuclide Conjugates (PRCs) Sales by Country (K Units), 2027–2032
 Table 28. North America Peptide-Radionuclide Conjugates (PRCs) Revenue by Country (US$ Million), 2021–2026
 Table 29. North America Peptide-Radionuclide Conjugates (PRCs) Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe Peptide-Radionuclide Conjugates (PRCs) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Country (K Units), 2021–2026
 Table 32. Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Country (K Units), 2027–2032
 Table 33. Europe Peptide-Radionuclide Conjugates (PRCs) Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe Peptide-Radionuclide Conjugates (PRCs) Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific Peptide-Radionuclide Conjugates (PRCs) Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific Peptide-Radionuclide Conjugates (PRCs) Sales by Region (K Units), 2021–2026
 Table 37. Asia Pacific Peptide-Radionuclide Conjugates (PRCs) Sales by Region (K Units), 2027–2032
 Table 38. Asia Pacific Peptide-Radionuclide Conjugates (PRCs) Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific Peptide-Radionuclide Conjugates (PRCs) Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America Peptide-Radionuclide Conjugates (PRCs) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America Peptide-Radionuclide Conjugates (PRCs) Sales by Country (K Units), 2021–2026
 Table 42. Latin America Peptide-Radionuclide Conjugates (PRCs) Sales by Country (K Units), 2027–2032
 Table 43. Latin America Peptide-Radionuclide Conjugates (PRCs) Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America Peptide-Radionuclide Conjugates (PRCs) Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa Peptide-Radionuclide Conjugates (PRCs) Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa Peptide-Radionuclide Conjugates (PRCs) Sales by Country (K Units), 2021–2026
 Table 47. Middle East and Africa Peptide-Radionuclide Conjugates (PRCs) Sales by Country (K Units), 2027–2032
 Table 48. Middle East and Africa Peptide-Radionuclide Conjugates (PRCs) Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa Peptide-Radionuclide Conjugates (PRCs) Revenue by Country (US$ Million), 2027–2032
 Table 50. Global Peptide-Radionuclide Conjugates (PRCs) Sales (K Units) by Type (2021–2026)
 Table 51. Global Peptide-Radionuclide Conjugates (PRCs) Sales (K Units) by Type (2027–2032)
 Table 52. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type (2021–2026)
 Table 53. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type (2027–2032)
 Table 54. Global Peptide-Radionuclide Conjugates (PRCs) Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global Peptide-Radionuclide Conjugates (PRCs) Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Type (2021–2026)
 Table 57. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Type (2027–2032)
 Table 58. Global Peptide-Radionuclide Conjugates (PRCs) Price (US$/Unit) by Type (2021–2026)
 Table 59. Global Peptide-Radionuclide Conjugates (PRCs) Price (US$/Unit) by Type (2027–2032)
 Table 60. Global Peptide-Radionuclide Conjugates (PRCs) Sales (K Units) by Application (2021–2026)
 Table 61. Global Peptide-Radionuclide Conjugates (PRCs) Sales (K Units) by Application (2027–2032)
 Table 62. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Application (2021–2026)
 Table 63. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Application (2027–2032)
 Table 64. Global Peptide-Radionuclide Conjugates (PRCs) Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global Peptide-Radionuclide Conjugates (PRCs) Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Application (2021–2026)
 Table 67. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Application (2027–2032)
 Table 68. Global Peptide-Radionuclide Conjugates (PRCs) Price (US$/Unit) by Application (2021–2026)
 Table 69. Global Peptide-Radionuclide Conjugates (PRCs) Price (US$/Unit) by Application (2027–2032)
 Table 70. Novartis Company Information
 Table 71. Novartis Description and Business Overview
 Table 72. Novartis Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 73. Novartis Peptide-Radionuclide Conjugates (PRCs) Product
 Table 74. Novartis Recent Developments/Updates
 Table 75. RadioMedix Company Information
 Table 76. RadioMedix Description and Business Overview
 Table 77. RadioMedix Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 78. RadioMedix Peptide-Radionuclide Conjugates (PRCs) Product
 Table 79. RadioMedix Recent Developments/Updates
 Table 80. Curium Pharma Company Information
 Table 81. Curium Pharma Description and Business Overview
 Table 82. Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 83. Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Product
 Table 84. Curium Pharma Recent Developments/Updates
 Table 85. Telix Pharmaceutical Company Information
 Table 86. Telix Pharmaceutical Description and Business Overview
 Table 87. Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 88. Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product
 Table 89. Telix Pharmaceutical Recent Developments/Updates
 Table 90. ITM Radiopharma Company Information
 Table 91. ITM Radiopharma Description and Business Overview
 Table 92. ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 93. ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Product
 Table 94. ITM Radiopharma Recent Developments/Updates
 Table 95. Grand Pharmaceutical Company Information
 Table 96. Grand Pharmaceutical Description and Business Overview
 Table 97. Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
 Table 98. Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product
 Table 99. Grand Pharmaceutical Recent Developments/Updates
 Table 100. Key Raw Materials Lists
 Table 101. Raw Materials Key Suppliers Lists
 Table 102. Peptide-Radionuclide Conjugates (PRCs) Distributors List
 Table 103. Peptide-Radionuclide Conjugates (PRCs) Customers List
 Table 104. Peptide-Radionuclide Conjugates (PRCs) Market Trends
 Table 105. Peptide-Radionuclide Conjugates (PRCs) Market Drivers
 Table 106. Peptide-Radionuclide Conjugates (PRCs) Market Challenges
 Table 107. Peptide-Radionuclide Conjugates (PRCs) Market Restraints
 Table 108. Research Programs/Design for This Report
 Table 109. Key Data Information from Secondary Sources
 Table 110. Key Data Information from Primary Sources
 Table 111. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Peptide-Radionuclide Conjugates (PRCs)
 Figure 2. Global Peptide-Radionuclide Conjugates (PRCs) Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Peptide-Radionuclide Conjugates (PRCs) Market Share by Type: 2025 & 2032
 Figure 4. Diagnostic PRCs Product Picture
 Figure 5. Therapeutic PRCs Product Picture
 Figure 6. Global Peptide-Radionuclide Conjugates (PRCs) Market Value by Application (US$ Million), 2021–2032
 Figure 7. Global Peptide-Radionuclide Conjugates (PRCs) Market Share by Application: 2025 & 2032
 Figure 8. Prostate Cancer
 Figure 9. Neuroendocrine Tumors
 Figure 10. Other
 Figure 11. Global Peptide-Radionuclide Conjugates (PRCs) Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 12. Global Peptide-Radionuclide Conjugates (PRCs) Market Size (US$ Million), 2021–2032
 Figure 13. Global Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), 2021–2032
 Figure 14. Global Peptide-Radionuclide Conjugates (PRCs) Average Price (US$/Unit), 2021–2032
 Figure 15. Peptide-Radionuclide Conjugates (PRCs) Report Years Considered
 Figure 16. Peptide-Radionuclide Conjugates (PRCs) Sales Share by Manufacturers in 2025
 Figure 17. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Share by Manufacturers in 2025
 Figure 18. Top 5 and Top 10 Global Peptide-Radionuclide Conjugates (PRCs) Players: Market Share by Revenue in Peptide-Radionuclide Conjugates (PRCs) in 2025
 Figure 19. Peptide-Radionuclide Conjugates (PRCs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 20. Global Peptide-Radionuclide Conjugates (PRCs) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 21. North America Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Country (2021–2032)
 Figure 22. North America Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Country (2021–2032)
 Figure 23. United States Peptide-Radionuclide Conjugates (PRCs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 24. Canada Peptide-Radionuclide Conjugates (PRCs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 25. Europe Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Country (2021–2032)
 Figure 26. Europe Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Country (2021–2032)
 Figure 27. Germany Peptide-Radionuclide Conjugates (PRCs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 28. France Peptide-Radionuclide Conjugates (PRCs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 29. U.K. Peptide-Radionuclide Conjugates (PRCs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 30. Italy Peptide-Radionuclide Conjugates (PRCs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 31. Russia Peptide-Radionuclide Conjugates (PRCs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 32. Asia Pacific Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Region (2021–2032)
 Figure 33. Asia Pacific Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Region (2021–2032)
 Figure 34. China Peptide-Radionuclide Conjugates (PRCs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 35. Japan Peptide-Radionuclide Conjugates (PRCs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 36. South Korea Peptide-Radionuclide Conjugates (PRCs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 37. India Peptide-Radionuclide Conjugates (PRCs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. Australia Peptide-Radionuclide Conjugates (PRCs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. China Taiwan Peptide-Radionuclide Conjugates (PRCs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. Southeast Asia Peptide-Radionuclide Conjugates (PRCs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Latin America Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Country (2021–2032)
 Figure 42. Latin America Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Country (2021–2032)
 Figure 43. Mexico Peptide-Radionuclide Conjugates (PRCs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. Brazil Peptide-Radionuclide Conjugates (PRCs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. Argentina Peptide-Radionuclide Conjugates (PRCs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 46. Colombia Peptide-Radionuclide Conjugates (PRCs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Middle East and Africa Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Country (2021–2032)
 Figure 48. Middle East and Africa Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Country (2021–2032)
 Figure 49. Turkey Peptide-Radionuclide Conjugates (PRCs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 50. Saudi Arabia Peptide-Radionuclide Conjugates (PRCs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 51. UAE Peptide-Radionuclide Conjugates (PRCs) Revenue Growth Rate (US$ Million), 2021–2032
 Figure 52. Global Sales Market Share of Peptide-Radionuclide Conjugates (PRCs) by Type (2021–2032)
 Figure 53. Global Revenue Market Share of Peptide-Radionuclide Conjugates (PRCs) by Type (2021–2032)
 Figure 54. Global Peptide-Radionuclide Conjugates (PRCs) Price (US$/Unit) by Type (2021–2032)
 Figure 55. Global Sales Market Share of Peptide-Radionuclide Conjugates (PRCs) by Application (2021–2032)
 Figure 56. Global Revenue Market Share of Peptide-Radionuclide Conjugates (PRCs) by Application (2021–2032)
 Figure 57. Global Peptide-Radionuclide Conjugates (PRCs) Price (US$/Unit) by Application (2021–2032)
 Figure 58. Peptide-Radionuclide Conjugates (PRCs) Value Chain
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions